In vivo studies on the oridonin-loaded nanostructured lipid carriers

References

• Chen CC, Tsai TH, Huang ZR, Fang JY. (2010). Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 74:474–482.
   PubMed Web of Science ®Google Scholar
• Dai W, Zhang D, Duan C, Jia L, Wang Y, Feng F, Zhang Q. (2010). Preparation and characteristics of oridonin-loaded nanostructured lipid carriers as a controlled-release delivery system. J Microencapsul 27:234–241.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W. (2008). Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm 355:321–327.
   PubMed Web of Science ®Google Scholar
• Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL, Wu JM. (2005). Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 337:224–231.
   PubMed Web of Science ®Google Scholar
• Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. (2005). Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces 45:167–173.
   PubMed Web of Science ®Google Scholar
• Joshi M, Pathak S, Sharma S, Patravale V. (2008). Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int J Pharm 364:119–126.
   PubMed Web of Science ®Google Scholar
• Joshi M, Patravale V. (2008). Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 346:124–132.
   PubMed Web of Science ®Google Scholar
• Li CY, Wang EQ, Cheng Y, Bao JK. (2011). Oridonin: An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics. Int J Biochem Cell Biol 43:701–704.
   PubMed Web of Science ®Google Scholar
• Li F, Weng Y, Wang L, He H, Yang J, Tang X. (2010). The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers. Int J Pharm 393:203–211.
   PubMed Web of Science ®Google Scholar
• Li S, Liu Y, Liu T, Zhao L, Zhao J, Feng N. (2011). Development and in-vivo assessment of the bioavailability of oridonin solid dispersions by the gas anti-solvent technique. Int J Pharm 411:172–177.
   PubMed Web of Science ®Google Scholar
• Lin XH, Li XW, Zheng LQ, Yu L, Zhang QQ, Liu WC. (2007). Preparation and characterization of monocaprate nanostructured lipid carriers. Colloid Surface A. 311:106–111.
   Web of Science ®Google Scholar
• Lou H, Gao L, Wei X, Zhang Z, Zheng D, Zhang D, Zhang X, Li Y, Zhang Q. (2011). Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice. Colloids Surf B Biointerfaces 87:319–325.
   PubMed Web of Science ®Google Scholar
• Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X, Yu Z, Zhang D, Zhang Q. (2009). In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm 379:181–186.
   PubMed Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 107:215–228.
   PubMed Web of Science ®Google Scholar
• zur Mühlen A, Schwarz C, Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery–drug release and release mechanism. Eur J Pharm Biopharm 45:149–155.
   PubMed Web of Science ®Google Scholar
• Müller RH, Jacobs C. (2002). Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm 237:151–161.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. (2002a). Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242:121–128.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. (2002b). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54 Suppl 1:S131–S155.
   PubMed Web of Science ®Google Scholar
• Obeidat WM, Schwabe K, Müller RH, Keck CM. (2010). Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 76:56–67.
   PubMed Web of Science ®Google Scholar
• Ren KK, Wang HZ, Xie LP, Chen DW, Liu X, Sun J, Nie YC, Zhang RQ. (2006). The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J Ethnopharmacol 103:176–180.
   PubMed Web of Science ®Google Scholar
• Tiwari R, Pathak K. (2011). Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 415:232–243.
   PubMed Web of Science ®Google Scholar
• Wang H, Ye Y, Pan SY, Zhu GY, Li YW, Fong DW, Yu ZL. (2011). Proteomic identification of proteins involved in the anticancer activities of oridonin in HepG2 cells. Phytomedicine 18:163–169.
   PubMed Web of Science ®Google Scholar
• Xing J, Zhang D, Tan T. (2007). Studies on the oridonin-loaded poly(D,L-lactic acid) nanoparticles in vitro and in vivo. Int J Biol Macromol 40:153–158.
   PubMed Web of Science ®Google Scholar
• Zhang P, Liu Y, Feng N, Xu J. (2008). Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm 355:269–276.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Liu JP, Qiao H, Liu H, Ni JM, Zhang WL, Shi YB. (2010). Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology. Powder Technol 197:120–128.
   Web of Science ®Google Scholar